LBLT.F Stock Overview
A biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lattice Biologics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -100.00% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LBLT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how LBLT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how LBLT.F performed against the US Market.
Price Volatility
| LBLT.F volatility | |
|---|---|
| LBLT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LBLT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LBLT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Guy Cook | n/a |
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; and acellular dermal matrix that provides a natural collagen tissue scaffold that promotes cellular ingrowth, tissue vascularization, and regeneration The company also develops amniotic fluid-based products, such as AmnioBoost and AmnioBlast. In addition, it sells traditional allografts for multi-disciplinary applications, including orthopedics, neurology, podiatry, and oral/maxillofacial.
Lattice Biologics Ltd. Fundamentals Summary
| LBLT.F fundamental statistics | |
|---|---|
| Market cap | US$128.00 |
| Earnings (TTM) | -US$951.65k |
| Revenue (TTM) | US$1.56m |
0.0x
P/S Ratio0.0x
P/E RatioIs LBLT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBLT.F income statement (TTM) | |
|---|---|
| Revenue | US$1.56m |
| Cost of Revenue | US$912.36k |
| Gross Profit | US$645.64k |
| Other Expenses | US$1.60m |
| Earnings | -US$951.65k |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did LBLT.F perform over the long term?
See historical performance and comparison